Analysts forecast that Cambrex Co. (NYSE:CBM) will announce sales of $184.15 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Cambrex’s earnings, with the highest sales estimate coming in at $185.04 million and the lowest estimate coming in at $183.27 million. Cambrex posted sales of $177.87 million during the same quarter last year, which would indicate a positive year over year growth rate of 3.5%. The business is expected to announce its next quarterly earnings results on Thursday, February 8th.
On average, analysts expect that Cambrex will report full-year sales of $184.15 million for the current financial year, with estimates ranging from $529.85 million to $537.22 million. For the next year, analysts anticipate that the firm will report sales of $542.03 million per share, with estimates ranging from $540.16 million to $543.90 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Cambrex.
Cambrex (NYSE:CBM) last announced its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.17. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The company had revenue of $182.28 million during the quarter, compared to the consensus estimate of $181.39 million. During the same period in the previous year, the company posted $1.23 earnings per share. Cambrex’s revenue for the quarter was up 2.5% on a year-over-year basis.
Cambrex (NYSE CBM) opened at $51.10 on Friday. Cambrex has a twelve month low of $42.55 and a twelve month high of $62.95. The stock has a market capitalization of $1,730.00, a P/E ratio of 16.75, a price-to-earnings-growth ratio of 1.24 and a beta of 2.38.
Hedge funds have recently made changes to their positions in the company. Advisor Group Inc. raised its stake in shares of Cambrex by 29.8% during the 2nd quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after buying an additional 615 shares during the period. Visionary Asset Management Inc. acquired a new position in shares of Cambrex during the 3rd quarter worth approximately $201,000. Trexquant Investment LP acquired a new position in shares of Cambrex during the 3rd quarter worth approximately $209,000. Flinton Capital Management LLC raised its stake in shares of Cambrex by 90.9% during the 2nd quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock worth $213,000 after buying an additional 1,700 shares during the period. Finally, Sei Investments Co. raised its stake in shares of Cambrex by 3,120.9% during the 3rd quarter. Sei Investments Co. now owns 4,155 shares of the biotechnology company’s stock worth $228,000 after buying an additional 4,026 shares during the period.
ILLEGAL ACTIVITY NOTICE: “Cambrex Co. (CBM) Expected to Announce Quarterly Sales of $184.15 Million” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.com-unik.info/2018/02/09/cambrex-co-cbm-expected-to-announce-quarterly-sales-of-184-15-million.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.